David Garrett, DPM
Podiatrist · Miami, OKNPI 1265412613
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (43.0%), education and food and beverage — rather than concentrated in one kind of arrangement. 7 manufacturers reported payments, led by Kerecis Limited at 57.1% of the total. Reporting peaked in 2022 at $1,408 and has fallen 89.3% since, to $151 in 2024.
Across 22 payments — averaging $138.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Kerecis Limited$2K
- Pylant Medical$972
- Smith+Nephew$118
- Johnson & Johnson$79
- Organogenesis Inc.$74
- Abbott$39
- plus $23 from 1 others
What the payments were for
- Travel & lodging$1,30843%
- Food & beverage$76325%
- Education$97232%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Kerecis Limited | 4 | $1,739 |
| Pylant Medical | 1 | $972 |
| Smith+Nephew | 7 | $118 |
| Johnson & Johnson | 5 | $79 |
| Organogenesis Inc. | 2 | $74 |
| Abbott | 2 | $39 |
| Bioventus LLC | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerecis Omega3 Marigen$4,562
- Kerecis Omega3 SurgiClose$2,121
- Kerecis Omega3 GraftGuide$1,671
How this compares
$3,043 in reported general payments places this provider in the 65th percentile of 54 podiatrist providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Terbinafine Hcl | 78 | $704 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 13 | $198 |
| Cephalexin | 12 | $122 |
Paid to pharmacies, not to this prescriber.
Other podiatrist in Miami
- David CavallaroOklahoma City$22K
- Ahmed BukshEdmond$17K
- Aerial AveryAda$13K
- Patricia BoehleOklahoma City$10K
- Kevin DuxMuskogee$8K
- Barinder BassiTahlequah$7K
- Greg RohdeNorman$7K
- Thomas WicksChickasha$6K
- Tera SantistevanSapulpa$5K
- James StoughEnid$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.